GH Research PLC (GHRS)
12.70
+0.34
(+2.75%)
USD |
NASDAQ |
May 22, 16:00
12.77
+0.07
(+0.55%)
After-Hours: 20:00
GH Research Cash from Investing (TTM): 8.71M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 8.71M |
December 31, 2023 | -54.10M |
September 30, 2023 | -138.72M |
June 30, 2023 | -138.72M |
March 31, 2023 | -138.70M |
December 31, 2022 | -84.69M |
September 30, 2022 | -0.068M |
Date | Value |
---|---|
June 30, 2022 | -0.103M |
March 31, 2022 | -0.093M |
December 31, 2021 | -0.104M |
September 30, 2021 | -0.085M |
June 30, 2021 | -0.035M |
March 31, 2021 | -0.021M |
December 31, 2020 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-138.72M
Minimum
Jun 2023
8.71M
Maximum
Mar 2024
-39.05M
Average
-0.098M
Median
Cash from Investing (TTM) Benchmarks
Amarin Corp PLC | 22.81M |
Jazz Pharmaceuticals PLC | -430.14M |
Prothena Corp PLC | -2.828M |
Iterum Therapeutics PLC | 25.44M |
Mural Oncology PLC | -127.59M |